Top ▲
Ligand name | ID | Synonyms | |||||||
A | Back to top | ||||||||
ABBV-3373 | 12917 | ADC 122 | |||||||
AbGn-168H | 10013 | AbGn-168, neihulizumab | |||||||
abrezekimab | 9806 | CDP7766, UCB-4144, UCB4144, VR-942 | |||||||
abrilumab | 11531 | AMG 181, AMG-181, MEDI-7183, MEDI7183 | |||||||
adalimumab | 4860 | D2E7, Humira® | |||||||
AFM13 | 10067 | AFM 13, AFM-13 | |||||||
alemtuzumab | 6770 | campath 1H, Campath®, campath-1H, Lemtrada® | |||||||
ALT-803 | 9615 | IL-15 N72D:IL-15RαSu/Fc, IL-15SA, N-803 | |||||||
AMG820 | 9106 | ||||||||
AMY109 | 12789 | AMY-109, H1009/L395-F1974m | |||||||
anatumomab mafenatox | 9947 | 5T4FabV13SEAD227A, ABR 214936, ABR-214936, ABR214936, pMB125, PNU 214936, PNU-214936, PNU214936, TTS-CD2 | |||||||
andecaliximab | 9510 | GS-5745, GS5745 | |||||||
anifrolumab | 8258 | anifrolumab-fnia, MDX-1333, MEDI-546, Saphnelo® | |||||||
atezolizumab | 7990 | MPDL3280A, Tecentriq® | |||||||
atibuclimab | 11326 | IC14 | |||||||
avdoralimab | 11345 | anti-hC5aR-32F3A6 GL, IPH-5401, NN-8210, NNC-0215-0384 | |||||||
avelumab | 8735 | Bavencio®, MSB-0010718C, MSB0010718C | |||||||
B | Back to top | ||||||||
basiliximab | 6879 | CHI-621, L04AC02, SDZ-CHI-621, Simulect® | |||||||
begelomab | 8691 | Begendina&rg; (proprietary name), BT 5/9, SAND 26 | |||||||
belantamab mafodotin | 11117 | belamaf, belantamab mafodotin-blmf, Blenrep®, GSK-2857916, GSK2857916 | |||||||
belimumab | 6887 | Benlysta®, hBlySmAb-1.1, LimphoStat-B, lymphostat-B | |||||||
benralizumab | 7674 | BIW-8405, Fasenra®, KHK4563, MEDI-563 | |||||||
bexmarilimab | 12907 | Clevegen, FP-1305, FP1305 | |||||||
bifikafusp alfa | 9756 | Darleukin, L19-IL2, L19IL2 | |||||||
bimekizumab | 9411 | bimekizumab-bkzx, Bimzelx®, CA028_0496, CDP4940, gL7gH9, UCB-4940, UCB4940, Zu-G1 | |||||||
blinatumomab | 7384 | Blincyto®, bscCD19xCD3, MEDI-538, MT-103, MT103 | |||||||
brazikumab | 9293 | AMG 139, AMG-139, MEDI2070 | |||||||
brentuximab vedotin | 6772 | Adcetris®, anti-CD30 ADC SGN-35, SGN 35 | |||||||
briakinumab | 9213 | ABT-874, J-695, J695, Ozespa | |||||||
brodalumab | 7540 | AMG-827, AMG827, Kyntheum®, Lumicef®, Siliq® | |||||||
BsAb (CD89-CD20) | 9833 | ||||||||
C | Back to top | ||||||||
cabiralizumab | 9107 | BMS-986227, FPA-008, FPA008 | |||||||
cadonilimab | 12966 | AK-104, AK104 | |||||||
camoteskimab | 13187 | AEVI 007, AEVI-007, AVTX 007, AVTX-007, CERC 007, CERC-007, MEDI 2338 | |||||||
camrelizumab | 9758 | INCSHR1210, SHR-1210 | |||||||
canakinumab | 6773 | ACZ 885, ACZ885, Ilaris® | |||||||
cemiplimab | 10090 | cemiplimab-rwlc, Libtayo®, REGN-2810, REGN2810, SAR-439684, SAR439684 | |||||||
certolizumab pegol | 6774 | CDP870, Cimzia®, PHA 738144 | |||||||
CFZ533 | 9802 | CFZ-533, iscalimab (proposed INN), NVP-CFZ533, OM11-62MF | |||||||
clazakizumab | 9195 | ALD-518, ALD518, BMS-945429 | |||||||
COVA322 | 10469 | ||||||||
crovalimab | 12790 | RG-6107, RG6107, SKY59 | |||||||
cusatuzumab | 9778 | ARGX-110, ARGX110, clone 41D12 | |||||||
D | Back to top | ||||||||
daclizumab | 6880 | L04AC01, RO-24-7375, Ro-247375, Zenapax® | |||||||
dapirolizumab pegol | 11123 | CDP-7657, CDP7657, DZP | |||||||
daratumumab | 7395 | 3003-005, Darzalex®, HuMax-CD38, JNJ-54767414 | |||||||
dectrekumab | 8714 | QAX-576, QAX576 | |||||||
divozilimab | 13087 | BCD 132, BCD-132, Ivlizi® | |||||||
dostarlimab | 11518 | ANB-011, dostarlimab-gxly, Jemperli®, TSR-042, WBP-285 | |||||||
dupilumab | 7574 | Dupixent®, REGN668, SAR231893 | |||||||
durvalumab | 7985 | anti-B7H1 monoclonal antibody, Imfinzi®, MEDI-4736, MEDI4736 | |||||||
DX-2507 | 9959 | ||||||||
E | Back to top | ||||||||
eculizumab | 6884 | h5G1.1, h5G1.1VHC, Soliris® | |||||||
efalizumab | 6593 | anti alphaL integrin, antiCD11 alpha, hu1124, Raptiva® | |||||||
efgartigimod alfa | 9777 | ARGX-113, efgartigimod alfa-fcab, Vyvgart® | |||||||
eldelumab | 9047 | BMS-936557, MDX-1100 | |||||||
elezanumab | 9290 | ABT-555, AE12-1Y-QL | |||||||
elotuzumab | 8361 | BMS-901608, Empliciti®, HuLuc63 | |||||||
elranatamab | 12889 | elranatamab-bcmm, Elrexfio®, PF-06863135, PF06863135 | |||||||
emactuzumab | 8944 | RG7155, RO5509554 | |||||||
emapalumab | 9295 | emapalumab-lzsg, Gamifant®, NI-0501, NI0501 | |||||||
enoblituzumab | 9589 | MGA-271, MGA271 | |||||||
enokizumab | 8934 | 7F3com-2H2, MEDI-528, MEDI528 | |||||||
envafolimab | 10492 | Envida®, KN-035, KN035 | |||||||
epcoritamab | 11442 | epcoritamab-bysp, Epkinly®, GEN-3013, GEN3013, Tepkinly® | |||||||
epratuzumab | 8088 | 90Y-DOTA-hLL2, 90Y-epratuzumab tetraxetan, 90Y-hLL2, AMG-412, IMMU-hLL2, LymphoCide® (proposed proprietary name) | |||||||
etrolizumab | 8407 | PRO145223, RG-7413, RG7413, rhuMAb Beta7 | |||||||
F | Back to top | ||||||||
fezakinumab | 9281 | ILV-094 | |||||||
fontolizumab | 9847 | HuZAF | |||||||
G | Back to top | ||||||||
galcanezumab | 8967 | clone III, Emgality®, galcanezumab-gnlm, LY-2951742, LY2951742 | |||||||
gemtuzumab ozogamicin | 6775 | CDP 771, CMA 676, hP67.6-calicheamicin, Mylotarg®, WAY-CMA 676 | |||||||
gevokizumab | 7394 | XOMA 052, XOMA-052 | |||||||
gimsilumab | 9624 | MORAb-022 | |||||||
golimumab | 6776 | CNTO-148, CNTO148, Simponi® | |||||||
GSK3050002 | 9623 | E6071, KANAb071 | |||||||
guselkumab | 7998 | CNTO-1959, Tremfya® | |||||||
I | Back to top | ||||||||
ianalumab | 10656 | VAY-736, VAY736 | |||||||
ibalizumab | 10208 | Hu5A8, ibalizumab-uiyk, TMB-355, TMB355, TNX-355, Trogarzo® | |||||||
ibritumomab tiuxetan | 6777 | IDEC-2B8, IDEC-Y2B8-yttrium ibritumomab tiuxetan, NSC-715848, Zevalin® | |||||||
imaprelimab | 9805 | PRX-003, PRX003 | |||||||
inclacumab | 12312 | HuMab 002, LC1004-002, RO-4905417, RO4905417 | |||||||
infliximab | 5004 | cA2, Inflectra®, Remicade®, Remsima®, SB2, TA-650, Zymfentra® (subcutaneous formulation) | |||||||
inotuzumab ozogamicin | 8266 | Besponsa®, CMC-544 | |||||||
ipilimumab | 6888 | MDX-010, MDX-101, MDX-CTLA-4, Yervoy® | |||||||
itolizumab | 9421 | Alzumab®, T1h | |||||||
ixekizumab | 7541 | LY-2439821, LY2439821, Taltz® | |||||||
L | Back to top | ||||||||
lebrikizumab | 7684 | Ebglyss®, MILR1444A, RG3637, TNX-650 | |||||||
lenzilumab | 8935 | KB-003, KB003 | |||||||
leronlimab | 10752 | PRO 140, PRO-140, PRO140, Vyrologix® | |||||||
ligelizumab | 8997 | CL-2C, NVP-QGE031, QGE031 | |||||||
lilotomab | 9950 | Betalutin®, HH1, tetulomab | |||||||
lintuzumab | 7983 | ACTIMAB®, HuM195, SGN-33, SMART M195 | |||||||
lirilumab | 9310 | 1-7F9, BMS-986015, IPH2102 | |||||||
litifilimab | 11122 | BIIB-059, BIIB059 | |||||||
lulizumab pegol | 8460 | BMS-931699, BMS931699 | |||||||
lutikizumab | 9297 | ABT-981, E26.13-SS-X3 | |||||||
LY3022855 | 9109 | IMC-CS4 | |||||||
M | Back to top | ||||||||
MAB92 | 9665 | ||||||||
magrolimab | 12652 | Hu5F9-G4 | |||||||
mavrilimumab | 7785 | CAM-3001, KPL-301 | |||||||
MCS110 | 9110 | ||||||||
mepolizumab | 7685 | Nucala®, SB-240563 | |||||||
mezagitamab | 10609 | TAK-079, TAK079 | |||||||
milatuzumab | 8267 | hLL1, IMMU-115 | |||||||
mirikizumab | 9846 | Antibody I [US9023358], LY-3074828, LY3074828, mirikizumab-mrkz, Omvoh® | |||||||
mogamulizumab | 6477 | KW-0761, mogamulizumab-kpkc, Poteligeo® | |||||||
monalizumab | 8323 | humZ270, IPH-2201, NN8765-3658 | |||||||
moxetumomab pasudotox | 7675 | CAT-8015, GCR-8015, HA22, Lumoxiti®, moxetumomab pasudotox-tdfk | |||||||
muromonab-CD3 | 6889 | L04AA02, OKT-3, Orthoclone Okt3® | |||||||
N | Back to top | ||||||||
namilumab | 10370 | AMG203, MT203 | |||||||
naptumomab estafenatox | 9948 | ABR-217620, ABR217620, Anyara (proposed trade name), TTS CD3, TTS-CD3 | |||||||
naratuximab emtansine | 9949 | IMGN-529, IMGN529, K7153A-SMCC-DM1 | |||||||
natalizumab | 6591 | AN100226, anti-alpha4 integrin, anti-VLA4, Tysabri® | |||||||
nemolizumab | 8720 | CD14152, CIM 331, CIM331, Mitchga® | |||||||
nivolumab | 7335 | BMS-936558, MDX-1106, ONO-4538, Opdivo® | |||||||
nurulimab | 12992 | BCD-145, BCD145 | |||||||
O | Back to top | ||||||||
obinutuzumab | 6941 | GA-101, GA101, Gazyva® | |||||||
ocrelizumab | 7580 | 2H7, Ocrevus®, PRO70769, RG1594 | |||||||
ofatumumab | 6778 | Arzerra®, GSK 1841157, GSK1841157, humax-CD20, Kesimpta® (subcutaneous), OMB-157, OMB157 | |||||||
oleclumab | 9596 | MEDI 9447, MEDI-9447 | |||||||
omalizumab | 6890 | IGE25, olizumab, R03DX05, RG-3648, rhumab-E25, Xolair® | |||||||
onfekafusp alfa | 9757 | Fibronum, L19TNF-alpha | |||||||
ontamalimab | 9340 | PF-00547659, PF-547659, SHP647 | |||||||
ordesekimab | 13046 | AMG-714, AMG714, MAb146B7, PRV-015 | |||||||
OSE-127 | 9604 | Effi-7 | |||||||
otilimab | 11132 | GSK-3196165, GSK3196165, MOR-103, MOR103 | |||||||
otlertuzumab | 9951 | CD37-SMIP, TRU-016, TRU016 | |||||||
ozoralizumab | 9638 | ATN-103, PF-5230896 | |||||||
P | Back to top | ||||||||
pascolizumab | 7786 | SB-240683 | |||||||
pateclizumab | 9854 | MLTA3698A, PRO283698, RG7416 | |||||||
pembrolizumab | 7499 | Keytruda®, lambrolizumab, MK-3475 | |||||||
penpulimab | 12347 | AK-105, AK105 | |||||||
perenostobart | 12103 | SRF-617, SRF617 | |||||||
plonmarlimab | 11644 | TJ 003234, TJ003234, TJM2 | |||||||
plozalizumab | 8921 | hu1D9, MLN-1202, MLN1202 | |||||||
polatuzumab vedotin | 8404 | ACD79B-VCMMAE, polatuzumab vedotin-piiq, Polivy®, RG-7596, RG7596, RO5541077-000 | |||||||
pozelimab | 12900 | pozelimab-bbfg, REGN-3918, REGN3918, Veopoz® | |||||||
prolgolimab | 12991 | BCD-100, BCD100 | |||||||
Q | Back to top | ||||||||
quilizumab | 8998 | 47H4 v5 hulgG1, MEMP1972A, RG-7449 | |||||||
R | Back to top | ||||||||
ravulizumab | 10168 | ALXN-1210, ALXN1210, ravulizumab-cwvz, Ultomiris® | |||||||
relatlimab | 9536 | BMS-986016, BMS986016, ONO-4482, Opdualag® (nivolumab + relatlimab-rmbw), relatlimab-rmbw | |||||||
remtolumab | 9597 | A-1230717, ABT-122 | |||||||
reslizumab | 8091 | CDP-835, CDP835, Cinqaero®, Cinqair®, JES1-39D10, SCH55700 | |||||||
retifanlimab | 11583 | hPD-1 mAb 7(1.2), INCMGA0012, MGA012, retifanlimab-dlwr, Zynyz® | |||||||
risankizumab | 8922 | ABBV-066, BI 655066, BI-655066, risankizumab-rzaa, Skyrizi® | |||||||
rituximab | 6780 | HSDB 7455, IDEC-C2B8, MabThera®, Rituxan® | |||||||
rocatinlimab | 13045 | AMG-451, AMG451, KHK-4083, KHK4083 | |||||||
rontalizumab | 9640 | 9F3v13, RhuMAB IFNalpha, rhuMAb interferon-α | |||||||
rovelizumab | 9598 | Hu23F2G, LeukArrest | |||||||
rozanolixizumab | 9801 | CA170_01519.g57 IgG4P, rozanolixizumab-noli, Rystiggo®, UCB-7665, UCB7665 | |||||||
S | Back to top | ||||||||
sarilumab | 7999 | Kevzara®, REGN88, SAR153191 | |||||||
satralizumab | 9093 | Enspryng®, RG-6168, RG6168, SA-237, SA237, sapelizumab (deprecated INN), satralizumab-mwge | |||||||
secukinumab | 8078 | AIN 457, AIN457, Cosentyx®, NVP-AIN457 | |||||||
sibeprenlimab | 12102 | VIS-649, VIS649 | |||||||
sifalimumab | 8257 | MDX-1103, MEDI-545, MEDI545 | |||||||
siltuximab | 7396 | cLLB8, CNTO 328, Sylvant® | |||||||
sintilimab | 12990 | IBI 308, IBI-308, IBI308, Tyvyt® | |||||||
sirukumab | 7989 | CNTO 136, CNTO-136, Plivensia (proposed trade name) | |||||||
sonelokimab | 10491 | IL17-MS3086, IL17MS3086, SEQ ID 836 [WO2012156219A1] | |||||||
spartalizumab | 10140 | NPV-PDR001, NPVPDR001, PDR-001, PDR001 | |||||||
spesolimab | 12169 | BI-655130, BI655130, spesolimab-sbzo, Spevigo® | |||||||
sutimlimab | 9807 | BIVV009, Enjaymo®, IPN-009, IPN009, sutimlimab-jome, TNT009 | |||||||
T | Back to top | ||||||||
tabalumab | 8000 | LY 2127399, LY2127399 | |||||||
tafasitamab | 11131 | Minjuvi®, Monjuvi®, MOR-208, MOR00208, MOR208, tafasitamab-cxix, Xmab5574 | |||||||
tebentafusp | 7378 | IMCgp100, Kimmtrak®, tebentafusp-tebn | |||||||
temelimab | 11530 | GNbAC1 | |||||||
teplizumab | 12252 | humanized OKT3, MGA031, PRV-031, teplizumab-mzwv, Tzield® | |||||||
tepoditamab | 10353 | MCLA-117, MCLA117, PB9122 | |||||||
teprotumumab | 10612 | R1507, RG-1507, RG1507, RV 001, RV-001, Tepezza®, teprotumumab-trbw | |||||||
tezepelumab | 8933 | AMG 157, AMG-157, MEDI-9929, MEDI9929, tezepelumab-ekko, Tezspire® | |||||||
tibulizumab | 10350 | LY-3090106, LY3090106 | |||||||
tildrakizumab | 8093 | Ilumetri®, Ilumya®, MK-3222, MK3222, SCH-900222, SCH900222, SUNPG1623, tildrakizumab-asmn | |||||||
timolumab | 9097 | 8c10, BTT-1023, BTT1023, r8c10, SI-3106, SI-636 | |||||||
tislelizumab | 9592 | Bai Zean®, BGB-A317, BGBA317, hu317-1/IgG4mt2, Tevimbra®, tislelizumab-jsgr | |||||||
tocilizumab | 6881 | Actemra®, R-1569, RG-1569, RHPM-1, RoActemra® | |||||||
tomaralimab | 9408 | OPN-305, OPN305, VK5A/H4 | |||||||
toripalimab | 12989 | JS-001, JS001, Loqtorzi®, toripalimab-tpzi | |||||||
tositumomab | 6781 | Bexxar®, V10XA53 | |||||||
tozorakimab | 12964 | MEDI-3506, MEDI3506 | |||||||
tralokinumab | 8001 | Adbry®, Adtralza®, BAK1.1, CAT-354, tralokinumab-ldrm | |||||||
tregalizumab | 9864 | BT-061, hB-F5 | |||||||
tremelimumab | 8462 | CP-675, CP-675,206, CP-675206, Imjudo®, ticilimumab, tremelimumab-actl | |||||||
U | Back to top | ||||||||
ublituximab | 8920 | Briumvi®, LFB-R603, TG-1101, TGTX-1101, ublituximab-xiiy | |||||||
ulocuplumab | 9161 | BMS-936564, MDX-1338 | |||||||
urelumab | 9311 | BMS 663513, BMS-663513 | |||||||
ustekinumab | 6885 | CNTO-1275, L04AC05, Stelara®, TT-20 | |||||||
utomilumab | 9244 | PF-05082566 | |||||||
V | Back to top | ||||||||
vadastuximab talirine | 9434 | SGN-CD33A | |||||||
varokibart | 12187 | ||||||||
vedolizumab | 7437 | Entyvio®, LDP-02, LDP02, MLN-0002, MLN-002, MLN002 | |||||||
veltuzumab | 8268 | hA20, IMMU-106 | |||||||
vobarilizumab | 8363 | ALX-0061 | |||||||
vunakizumab | 9296 | SHR-1314 | |||||||
X | Back to top | ||||||||
Xilonix TN | 8528 | ||||||||
Z | Back to top | ||||||||
zigakibart | 12101 | BION-1301, BION1301, clone 14_1G.15 | |||||||
zimberelimab | 12349 | AB-122, AB122, GLS-010 | |||||||